Solvay Joins Advanced Materials Venture Capital Fund

Solvay today announces that it has joined Pangaea Ventures Fund II, LP, a Vancouver, Canada -based venture capital fund focused on advanced materials, including nanotechnology, energy and environmental technology. Solvay will contribute an undisclosed amount of capital to the fund, whose lead investors also include BASF and Ciba Specialty Chemicals.

Solvay’s commitment reflects its strategy to foster new business opportunities in information and communications technologies (ICT). The Group’s principal areas of interest in next-generation ICT materials include light-emitting polymers, electricity conductive polymers and conductive inks.

In addition to its own in-house research efforts, Solvay explores the development of new activities through venturing and partnerships with pioneering research organizations. The Group has recently concluded an agreement with the Georgia Institute of Technology’s Center for Organic Photonics and Electronics (COPE) to fund research in organic light-emitting diodes (OLEDs). As for venturing, the participation in funds and subsequent investment in pioneering growth companies gives Solvay essential insight into the most recent developments of ground-breaking markets and technologies.

“We are confident that our participation in Pangaea Ventures Fund will stimulate the further development of Solvay’s new advanced materials activities, through close contact with innovation in North America,” commented Léopold Demiddeleer, Corporate R&D and New Business Development Director, Solvay. “Our intention is to build a long lasting partnership to reinforce Solvay’s advanced materials platform in information and communications technologies – which we identified as a key area of development for the Group,” he added.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.